Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (23.04.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 23.04.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ed to supplement the Company’s disclosure under Item 5.02 of the Original Report. The Original Report otherwise remains |
Stammdaten
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Unternehmen & Branche
| Name | CareDx, Inc. |
|---|---|
| Ticker | CDNA |
| CIK | 0001217234 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Diagnostics & Research |
| SIC | 8071 · Services-Medical Laboratories |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,03 Mrd. USD |
| Beta | 2,54 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 379,805,000 | -21,354,000 | -0.40 | 413,228,000 | 303,101,000 |
| 2025-09-30 | 10-Q | 100,055,000 | 1,675,000 | 0.03 | 432,307,000 | 311,140,000 |
| 2025-06-30 | 10-Q | 86,679,000 | -8,568,000 | -0.16 | 444,257,000 | 327,370,000 |
| 2025-03-31 | 10-Q | 84,685,000 | -10,353,000 | -0.19 | 489,638,000 | 379,349,000 |
| 2024-12-31 | 10-K | 333,785,000 | 52,549,000 | 0.93 | 491,050,000 | 378,433,000 |
| 2024-09-30 | 10-Q | 82,883,000 | -10,637,000 | -0.20 | 476,985,000 | 273,246,000 |
| 2024-06-30 | 10-Q | 92,274,000 | -4,623,000 | -0.09 | 466,777,000 | 264,669,000 |
| 2024-03-31 | 10-Q | 72,049,000 | -19,888,000 | -0.38 | 452,406,000 | 256,225,000 |
| 2023-12-31 | 10-K | 280,324,000 | -190,284,000 | -3.54 | 466,826,000 | 261,328,000 |
| 2023-09-30 | 10-Q | 67,192,000 | -23,485,000 | -0.43 | 501,180,000 | 394,134,000 |
| 2023-06-30 | 10-Q | 70,301,000 | -24,953,000 | -0.46 | 514,820,000 | 405,213,000 |
| 2023-03-31 | 10-Q | 77,262,000 | -23,749,000 | -0.44 | 528,217,000 | 420,021,000 |
| 2022-12-31 | 10-K | 321,793,000 | -76,613,000 | -1.44 | 542,991,000 | 430,911,000 |
| 2022-09-30 | 10-Q | 79,359,000 | -16,939,000 | -0.32 | 544,511,000 | 436,679,000 |
| 2022-06-30 | 10-Q | 80,634,000 | -21,697,000 | -0.41 | 541,288,000 | 443,549,000 |
| 2022-03-31 | 10-Q | 79,416,000 | -19,648,000 | -0.37 | 546,711,000 | 457,544,000 |
| 2021-12-31 | 10-K | 296,397,000 | -30,662,000 | -0.59 | 566,621,000 | 465,876,000 |
| 2021-09-30 | 10-Q | 75,589,000 | -11,897,000 | -0.23 | 563,172,000 | 472,147,000 |
| 2021-06-30 | 10-Q | 74,188,000 | -1,927,000 | -0.04 | 557,415,000 | 479,843,000 |
| 2021-03-31 | 10-Q | 67,400,000 | -687,000 | -0.01 | 541,223,000 | 471,546,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | Hanna John Walter JR | Director, Officer, President and CEO | Open Market Sale | -10,282 | 21.12 | -217,155.84 | -128,7% | |
| 2026-02-03 | Novack Jeffrey Adam | Officer, Secretary and General Counsel | Open Market Sale | -4,441 | 20.56 | -91,286.09 | -54,1% | |
| 2026-01-22 | Hanna John Walter JR | Director, Officer, President and CEO | Open Market Sale | -19,280 | 21.16 | -408,022.64 | -241,8% | |
| 2026-01-21 | Hanna John Walter JR | Director, Officer, President and CEO | Open Market Sale | -200 | 21.00 | -4,200.00 | -2,5% | |
| 2026-01-15 | Hanna John Walter JR | Director, Officer, President and CEO | Open Market Sale | -10,156 | 21.05 | -213,804.11 | -126,7% | |
| 2025-12-04 | Novack Jeffrey Adam | Officer, Secretary and General Counsel | Open Market Sale | -286 | 19.75 | -5,648.36 | -3,3% | |
| 2025-12-04 | Novack Jeffrey Adam | Officer, Secretary and General Counsel | Open Market Sale | -7,007 | 19.15 | -134,156.02 | -79,5% | |
| 2025-11-07 | Novack Jeffrey Adam | Officer, Secretary and General Counsel | Open Market Sale | -2,688 | 15.52 | -41,722.87 | -24,7% | |
| 2025-08-05 | Novack Jeffrey Adam | Officer, Secretary and General Counsel | Open Market Sale | -2,688 | 12.79 | -34,380.60 | -20,4% | |
| 2025-07-07 | Maag Peter | Director | Open Market Sale | -10,000 | 18.58 | -185,831.00 | -110,1% | |
| 2025-06-18 | Valantine Hannah | Director | Open Market Sale | -10,570 | 19.16 | -202,565.59 | -120,0% | |
| 2025-06-17 | Maag Peter | Director | Open Market Sale | -10,000 | 19.24 | -192,420.00 | -114,0% | |
| 2025-05-12 | COURNOYER CHRISTINE | Director | Open Market Sale | -29,136 | 15.96 | -465,022.21 | -275,5% | |
| 2025-05-06 | COURNOYER CHRISTINE | Director | Open Market Sale | -16,700 | 14.13 | -235,929.25 | -139,8% | |
| 2025-05-05 | Novack Jeffrey Adam | Officer, Secretary and General Counsel | Open Market Sale | -2,688 | 14.70 | -39,513.60 | -23,4% | |
| 2025-04-30 | Maag Peter | Director | Open Market Sale | -13,281 | 17.23 | -228,795.77 | -135,6% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.